SNCAIP

Synphilin-1 (SNCAIP) is a cytoplasmic neuronal protein that functions as a direct binding partner of alpha-synuclein and a contributor to the formation of Lewy body-like cytoplasmic inclusions characteristic of alpha-synucleinopathies (PMID:10319874, PMID:16595633). The protein was identified through its physical interaction with alpha-synuclein, and co-expression of the two proteins—neither sufficient alone—drives the formation of eosinophilic cytoplasmic inclusions in mammalian cells, with synphilin-1 colocalizing with alpha-synuclein in human brain neuropil (PMID:10319874, PMID:10967135). An aggregation-prone isoform, synphilin-1A, encoded from the same gene through alternative exon organization and translation start, binds alpha-synuclein, drives intracellular aggregation, and is present in Lewy bodies and detergent-insoluble brain fractions of Parkinson's disease and Diffuse Lewy Body disease patients; the neuronal toxicity it produces is attenuated when its inclusions sequester alpha-synuclein, indicating inclusion formation is a protective response to a toxic soluble species (PMID:16595633). Synphilin-1 aggregation and toxicity are promoted by oxidation and glycation, as loss of the glyoxalase and aldose reductase detoxification systems in yeast enhances inclusion formation alongside oxidative stress and impaired autophagic clearance (PMID:33562355), and neuronal expression of synphilin-1 in Drosophila produces dopaminergic and serotonergic neurodegeneration with Parkinson-like motor and non-motor phenotypes (PMID:36857384). Beyond its link to ubiquitin-mediated protein degradation (PMID:15322916), the enzymatic and structural mechanism of synphilin-1 has not been characterized in the available corpus.

1. 1999 High

   Establishing that synphilin-1 is a physical partner of alpha-synuclein answered whether alpha-synuclein has dedicated neuronal interactors that could nucleate the inclusions seen in Parkinson's disease.

   Evidence Yeast two-hybrid screen, in vivo co-immunoprecipitation from neurons, and co-transfection inclusion assay in HEK 293 cells

   PMID:10319874

   Open questions at the time

   • Binding interface and stoichiometry of the synphilin-1/alpha-synuclein complex not defined
   • Whether inclusion formation is protective or pathogenic not resolved by this study
   • No endogenous neuronal function assigned
2. 2000 Medium

   Genomic characterization fixed the gene structure and chromosomal location and confirmed that endogenous synphilin-1 protein colocalizes with alpha-synuclein in human brain, anchoring the interaction in native tissue.

   Evidence Genomic cloning/sequencing, chromosomal mapping, and immunohistochemistry of postmortem human brain

   PMID:10967135

   Open questions at the time

   • No functional domain mapping
   • Subcellular compartment within neurons not specified
3. 2004 Low

   Linking synphilin-1 to ubiquitin-mediated degradation and identifying a disease-associated R621C variant connected the protein to protein turnover pathways and to PD susceptibility.

   Evidence Review summarizing in vitro interaction/degradation studies and genetic variant identification in two patients

   PMID:15322916

   Open questions at the time

   • Review-level summary without primary experimental detail in abstract
   • R621C causality not established beyond two-patient association
   • Specific E3 ligase/proteasome mechanism not defined
4. 2006 High

   Discovery of the synphilin-1A isoform clarified that an alternatively organized transcript of the same gene is the aggregation-prone, disease-relevant species, and that inclusion formation buffers its intrinsic toxicity.

   Evidence Molecular cloning, co-transfection and neuronal toxicity assays, patient tissue immunohistochemistry, and detergent fractionation of brain

   PMID:16595633

   Open questions at the time

   • Molecular determinant making synphilin-1A more aggregation-prone than synphilin-1 not identified
   • Mechanism by which inclusions reduce toxicity unresolved
   • Relative in vivo abundance of the two isoforms unknown
5. 2021 Medium

   Yeast genetics established that oxidative and glycation stress, via the glyoxalase and aldose reductase systems and autophagy, are upstream modulators of synphilin-1 aggregation and toxicity.

   Evidence Expression of human SNCAIP in Glo1/Glo2/Gre3-deletion yeast with inclusion imaging, growth, and oxidative stress readouts

   PMID:33562355

   Open questions at the time

   • Direct sites of oxidation/glycation on synphilin-1 not mapped
   • Relevance of yeast autophagy link to neuronal clearance not demonstrated
   • Single-lab model
6. 2023 Medium

   Cell-type-specific expression in Drosophila demonstrated that synphilin-1 is sufficient to drive neurodegeneration and Parkinson-like phenotypes in vivo, with distinct dopaminergic and serotonergic contributions.

   Evidence Transgenic neuron-type-specific expression in Drosophila with motor/olfactory/visual behavioral assays, survival analysis, and nicotine treatment

   PMID:36857384

   Open questions at the time

   • Molecular pathway linking synphilin-1 expression to neuronal death not defined
   • Role of endogenous fly alpha-synuclein ortholog absent
   • Mechanism of nicotine rescue unknown

• The normal cellular function of synphilin-1 and the biochemical mechanism by which it engages ubiquitin-mediated degradation remain undefined, as does the structural basis of its alpha-synuclein binding and aggregation.
• No catalytic activity established
• No structure of synphilin-1 or its complexes
• Physiological (non-disease) role unknown